Nalmefene - TaiwanJ Pharmaceuticals

Drug Profile

Nalmefene - TaiwanJ Pharmaceuticals

Alternative Names: JKB-121; Nalmetrene - TaiwanJ Pharmaceuticals

Latest Information Update: 05 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jenken Biosciences
  • Developer Duke University Medical Center; TaiwanJ Pharmaceuticals
  • Class Antidotes; Morphinans; Neuroprotectants; Small molecules; Smoking cessation therapies
  • Mechanism of Action Opioid receptor antagonists; Toll-like receptor 4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-alcoholic steatohepatitis

Most Recent Events

  • 29 Sep 2015 TaiwanJ Pharmaceuticals has patents pending for nalmefene in USA and other countries
  • 28 Sep 2015 Phase-I clinical trials in Non-alcoholic steatohepatitis in USA (unspecified route) before September 2015 (TaiwanJ Pharmaceuticals Pipeline, September 2015)
  • 28 Sep 2015 TaiwanJ Pharmaceuticals files an IND application with US FDA in USA for Non-alcoholic steatohepatitis before September 2015 (TaiwanJ Pharmaceuticals website, September 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top